| 产品编号 | BIO0940SM |
| 英文名称 | Anti-Ang2 & VEGFA Reference Antibody (Vanucizumab Biosimilar) |
| 中文名称 | |
| 别 名 | Angiopoietin 2 & VEGF-A; Vanucizumab |
| 抗体来源 | |
| 克隆类型 | Monoclonal |
| 克 隆 号 | |
| 交叉反应 | Human |
| 产品应用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 146.89 kDa |
| 检测分子量 | |
| 性 状 | Lyophilized |
| 亚 型 | IgG-like |
| 纯化方法 | Protein A |
| 缓 冲 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存条件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 | |
| 产品图片 |
Co-incubation of Vanucizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Vanucizumab can neutralize VEGF-165, and the IC50 was 1.075 nM.
Vanucizumab bound to VEGFA protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vanucizumab bound to in huVEGFA-His, and the EC50 was 0.009 nM.
Vanucizumab bound to ANG2 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vanucizumab bound to in huANG2-His, and the EC50 was 0.288 nM.
The purity of Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) is more than 95%, determined by SEC-HPLC.
Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 96%.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
